NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Kiniksa's financial performance in Q2 2022 showed ARCALYST's continued momentum and strategic portfolio expansion.
Kiniksa Pharmaceuticals reported ARCALYST net revenue of $27.0 million for Q2 2022. The company anticipates $100 million in upfront and near-term proceeds from the vixarelimab global license agreement and expects cash reserves to fund operations into at least 2025.
- ARCALYST net revenue reached $27.0 million in Q2 2022.
- Full-year 2022 net revenue for ARCALYST is expected to be $115 - $130 million.
- The vixarelimab global license agreement is expected to generate $100 million in upfront and near-term proceeds.
- Cash reserves are projected to fund operations into at least 2025 following the vixarelimab agreement.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$27M
Revenue by segment
Kiniksa · $27M total across 1 segment · Q2 2022
- ARCALYST$27M-14.8%100.0%
Forward guidance
Kiniksa expects ARCALYST net revenue for full-year 2022 to be between $115 million and $130 million. The company plans to evolve its sales operation with approximately 20 additional field sales representatives in the fourth quarter of 2022.
Tailwinds
- ARCALYST net revenue for full-year 2022 expected to be between $115 million and $130 million
- Cash reserves expected to fund operations into at least 2025 following the close of the vixarelimab global license agreement with Genentech
- Plans to evolve sales operation with approximately 20 additional field sales representatives in the fourth quarter of 2022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro